AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22257341 — intervention group
Group type: EXPERIMENTAL
Intervention: Raypex 5
Number of subjects: 30
Study 22257341 — intervention group
Group type: EXPERIMENTAL
Intervention: ProPex II
Number of subjects: 30
Study 19174792 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3 (450‐1,800 billion bacteria/day)
Number of subjects: 29
Study 19174792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 19174792 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3
Number of subjects: 29
Study 17557453 — intervention group
Group type: EXPERIMENTAL
Intervention: eszopiclone 3 mg (cotherapy)
Number of subjects: 0
Study 17557453 — intervention group
Group type: COMPARATOR
Intervention: placebo (monotherapy)
Number of subjects: 0
Study 15805382 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 2-dose regimen of TIV administered in the fall
Number of subjects: 259
Study 15805382 — intervention group
Group type: EXPERIMENTAL
Intervention: Early schedule of a single spring dose followed by a fall dose of TIV
Number of subjects: 259
Study 15805382 — intervention group
Group type: EXPERIMENTAL
Intervention: TIV with concomitant vaccines
Number of subjects: 259
Study 15805382 — intervention group
Group type: COMPARATOR
Intervention: TIV (both groups)
Number of subjects: 259
Study 12087544 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching treatments (various concentrations) for 7 or 14 days
Number of subjects: 63
Study 12087544 — intervention group
Group type: COMPARATOR
Intervention: Control group (water instead of bleaching gel)
Number of subjects: 63
Study 9854805 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA (Personal Digital Assistant)
Number of subjects: 136
Study 9854805 — intervention group
Group type: COMPARATOR
Intervention: Computer
Number of subjects: 136
Study 9854805 — intervention group
Group type: COMPARATOR
Intervention: Paper method
Number of subjects: 136
Study 7896983 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior skills training HIV-risk reduction intervention (6 sessions)
Number of subjects: 34
Study 7896983 — intervention group
Group type: COMPARATOR
Intervention: Standard HIV education
Number of subjects: 34
Study 2694604 — intervention group
Group type: EXPERIMENTAL
Intervention: 250, 500, or 1,000 mg/kg of IVIG plus antibiotics
Number of subjects: 30
Study 2694604 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 30
Study 820104 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (20 mg)
Number of subjects: 20
Study 820104 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (5 mg)
Number of subjects: 20
Study 30500086 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 74
Study 30500086 — intervention group
Group type: COMPARATOR
Intervention: No-alcohol control beverage
Number of subjects: 74
Study 28030534 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5*1/*3 allele
Number of subjects: 37
Study 28030534 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5*3/*3 and CYP3A5*1/*3 carrier subgroups
Number of subjects: 37
Study 28030534 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients younger than 10 years
Number of subjects: 37
Study 28030534 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients off steroids
Number of subjects: 37
Study 25537522 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Awareness Practices (MAPS) intervention
Number of subjects: 71
Study 25537522 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 71
Study 23817002 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepitel One (soft silicone wound contact layer)
Number of subjects: 43
Study 23817002 — intervention group
Group type: COMPARATOR
Intervention: Bridal Veil and staples
Number of subjects: 43
Study 21563503 — intervention group
Group type: EXPERIMENTAL
Intervention: Jingyuankang capsule
Number of subjects: 58
Study 21563503 — intervention group
Group type: COMPARATOR
Intervention: Leucogen tablet
Number of subjects: 58
Study 19290019 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) combined with ongoing antiandrogen (AA) treatment
Number of subjects: 86
Study 19290019 — intervention group
Group type: COMPARATOR
Intervention: NORM (age-matched controls without a cancer diagnosis)
Number of subjects: 86
Study 16773343 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical investigation course for surgeons
Number of subjects: 24
Study 15070006 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with TBI
Number of subjects: 18
Study 15070006 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 18
Study 11242482 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sham feeding a low-fat meal (6 g fat)
Number of subjects: 10
Study 11242482 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sham feeding a moderate-fat meal (38 g fat)
Number of subjects: 10
Study 11242482 — intervention group
Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 10
Study 9287227 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir, zidovudine, and lamivudine
Number of subjects: 1156
Study 9287227 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine and lamivudine alone
Number of subjects: 1156
Study 8420235 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 2500
Study 8420235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study 29128975 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 32
Study 29128975 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 32
Study 27089045 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional support coping
Number of subjects: 350
Study 27089045 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance coping
Number of subjects: 350
Study 27089045 — intervention group
Group type: EXPERIMENTAL
Intervention: Denial coping
Number of subjects: 350
Study 27089045 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐blame coping
Number of subjects: 350
Study 24919564 — intervention group
Group type: EXPERIMENTAL
Intervention: MEND intervention (Mind, Exercise, Nutrition..Do it!) for childhood overweight or obesity, 10 weeks duration, 2 sessions/week.
Number of subjects: 21932
Study 23387822 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (intraarterial thrombolysis with recombinant tissue plasminogen activator [t‐PA], mechanical clot disruption or retrieval, or a combination of these approaches)
Number of subjects: 362
Study 23387822 — intervention group
Group type: COMPARATOR
Intervention: Intravenous t‐PA
Number of subjects: 362
Study 23387822 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 362
Study 19633060 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (BPT) plus Routine Clinical Care (RCC)
Number of subjects: 94
Study 19633060 — intervention group
Group type: COMPARATOR
Intervention: Routine Clinical Care (RCC) alone
Number of subjects: 94
Study 18761238 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5 microg/kg bolus, 0.05 microg/kg per min infusion)
Number of subjects: 30
Study 18761238 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (1 microg/kg bolus, 0.5 microg/kg bolus doses)
Number of subjects: 30
Study 18761238 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 30
Study 18761238 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 30
Study 16471102 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg IV administered twice
Number of subjects: 50
Study 16471102 — intervention group
Group type: COMPARATOR
Intervention: Tramadol 50 mg IV administered twice
Number of subjects: 50
Study 12939421 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day
Number of subjects: 616
Study 12939421 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg/day (after 5 mg/day for the first 28 days)
Number of subjects: 616
Study 12939421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 616
Study 10481525 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunofluorescence with MAC‐1, MAC‐31, NSE and anti‐Fucosyl‐GM1 (PF3) antibodies
Number of subjects: 32
Study 10481525 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 patients with other malignancies)
Number of subjects: 32
Study 8784635 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate (one drop at the end of surgery) in the NG-T group
Number of subjects: 39
Study 8784635 — intervention group
Group type: COMPARATOR
Intervention: No treatment in the NG group
Number of subjects: 39
Study 8784635 — intervention group
Group type: COMPARATOR
Intervention: No treatment in the G group
Number of subjects: 39
Study 1810999 — intervention group
Group type: EXPERIMENTAL
Intervention: Dibenzoylmethane derivatives
Number of subjects: 0
Study 1810999 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dibenzoylmethane derivative and physical agents
Number of subjects: 0
Study 1810999 — intervention group
Group type: COMPARATOR
Intervention: Physical agents
Number of subjects: 0
Study 6925982 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intrapleural injection of BCG
Number of subjects: 118
Study 6925982 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 118
Study 31823462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cancer screening participation
Number of subjects: 2408
Study 31823462 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, social status, knowledge of cervical cancer screening, and baseline screening outcome
Number of subjects: 2408
Study 29777003 — intervention group
Group type: EXPERIMENTAL
Intervention: Aducanumab (1 mg/kg)
Number of subjects: 0
Study 29777003 — intervention group
Group type: EXPERIMENTAL
Intervention: Aducanumab (3 mg/kg)
Number of subjects: 0
Study 29777003 — intervention group
Group type: EXPERIMENTAL
Intervention: Aducanumab (6 mg/kg)
Number of subjects: 0
Study 29777003 — intervention group
Group type: EXPERIMENTAL
Intervention: Aducanumab (10 mg/kg)
Number of subjects: 0
Study 29777003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28895777 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitatory KT
Number of subjects: 33
Study 28895777 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory KT
Number of subjects: 33
Study 28895777 — intervention group
Group type: COMPARATOR
Intervention: Sham KT
Number of subjects: 33
Study 28895777 — intervention group
Group type: COMPARATOR
Intervention: Untaped condition
Number of subjects: 33
Study 24682319 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (50 mg/week)
Number of subjects: 120
Study 24682319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 24682319 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 120
Study 24768239 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 666
Study 24768239 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 666
Study 24768239 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 666
Study 22476230 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan treatment (+ thiazide diuretics)
Number of subjects: 310
Study 19235080 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention with loss frame messaging
Number of subjects: 0
Study 19235080 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention with gain frame messaging
Number of subjects: 0
Study 18410608 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of Talpha1 (1.6 mg subcutaneously, twice a week) and lamivudine (100 mg orally, daily) for 24 weeks
Number of subjects: 67
Study 18410608 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine monotherapy continuously
Number of subjects: 67
Study 18410608 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of Talpha1 and lamivudine
Number of subjects: 67
Study 15752410 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with caudal catheter placement (AD group)
Number of subjects: 42
Study 15752410 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia with cephalad catheter placement (AU group)
Number of subjects: 42
Study 15752410 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with caudal catheter placement (HD group)
Number of subjects: 42
Study 15752410 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia with cephalad catheter placement (HU group)
Number of subjects: 42
Study 12016348 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic field treatment
Number of subjects: 192
Study 12016348 — intervention group
Group type: COMPARATOR
Intervention: Standard medication (diclofenac and tizanidine)
Number of subjects: 192
Study 10463630 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose drink
Number of subjects: 0
Study 10463630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8830065 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 to 200 mg per day for 8 weeks)
Number of subjects: 52
Study 8830065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 2337035 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg daily
Number of subjects: 40
Study 2337035 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg twice daily
Number of subjects: 40
Study 2337035 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg daily
Number of subjects: 40
Study 2337035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 35196 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (10-60 mg daily)
Number of subjects: 11
Study 35196 — intervention group
Group type: COMPARATOR
Intervention: Clobazam (49 mg daily)
Number of subjects: 11
Study 31216852 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative systemic therapy
Number of subjects: 126
Study 28674122 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally targeted lifestyle intervention (individual counselling using motivational interviewing, family session, cooking classes, supervised physical activity programme)
Number of subjects: 536
Study 28674122 — intervention group
Group type: COMPARATOR
Intervention: Generic lifestyle advice (control group)
Number of subjects: 536
Study 28674122 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally targeted lifestyle intervention
Number of subjects: 536
Study 26510728 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger children (aged <12 years)
Number of subjects: 0
Study 26510728 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents (aged 12-18 years)
Number of subjects: 0
Study 26510728 — intervention group
Group type: COMPARATOR
Intervention: Adults
Number of subjects: 0
Study 23242758 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial lysate (Escherichia coli and Enterococcus faecalis), prophylactic treatment for 26 weeks
Number of subjects: 606
Study 23242758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study 20554358 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade dissection (n=20)
Number of subjects: 40
Study 20554358 — intervention group
Group type: COMPARATOR
Intervention: Retrograde dissection (n=20)
Number of subjects: 40
Study 19292625 — intervention group
Group type: EXPERIMENTAL
Intervention: Teledermatology
Number of subjects: 0
Study 19292625 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 17923543 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (2.5 mg)
Number of subjects: 62
Study 17923543 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT)
Number of subjects: 62
Study 15314546 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interleukin-2 (3 x 10(6) IU/m2/day) administered daily for 6 weeks with a weekly melanoma peptide vaccine.
Number of subjects: 40
Study 11332212 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal administration of 1 mg gemeprost (group 2A, n: 17)
Number of subjects: 61
Study 11332212 — intervention group
Group type: COMPARATOR
Intervention: Surgical management (curettage, group 2B, n: 17)
Number of subjects: 61
Study 11332212 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy management (group 1, n: 27)
Number of subjects: 61
Study 9329410 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (1 unit per milliliter in umbilical catheter infusate)
Number of subjects: 113
Study 9329410 — intervention group
Group type: COMPARATOR
Intervention: No heparin (control group)
Number of subjects: 113
Study 9329410 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal indomethacin use
Number of subjects: 113
Study 7942578 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil enriched in omega-3 fatty acids
Number of subjects: 20
Study 7942578 — intervention group
Group type: COMPARATOR
Intervention: Vegetable oil enriched in oleic acid
Number of subjects: 20
Study 3357072 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention involving lecture, feedback, and checklists during ambulatory care rotation
Number of subjects: 28
Study 3357072 — intervention group
Group type: COMPARATOR
Intervention: Control group (residents not exposed to the program)
Number of subjects: 28
Study 30043885 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention (BrInter, n = 45)
Number of subjects: 90
Study 30043885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention with presentation of an educational video (InInterV, n = 45)
Number of subjects: 90
Study 30043885 — intervention group
Group type: COMPARATOR
Intervention: Both groups combined
Number of subjects: 90
Study 30043885 — intervention group
Group type: COMPARATOR
Intervention: Craving (moderate or intense)
Number of subjects: 90
Study 28271943 — intervention group
Group type: EXPERIMENTAL
Intervention: Talus Control Foot Orthoses (TCFOs)
Number of subjects: 40
Study 28271943 — intervention group
Group type: COMPARATOR
Intervention: Rigid Foot Orthoses (RFOs)
Number of subjects: 40
Study 26174571 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-splint multimodal therapy plus stabilisation splint (NS+S)
Number of subjects: 181
Study 26174571 — intervention group
Group type: COMPARATOR
Intervention: Non-splint multimodal therapy (NS)
Number of subjects: 181
Study 24093846 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 304
Study 24093846 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (TT)
Number of subjects: 304
Study 21167565 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar plasma vaporization of bladder tumors (BPV-BT)
Number of subjects: 120
Study 21167565 — intervention group
Group type: COMPARATOR
Intervention: Monopolar transurethral resection of bladder tumors (TURBT)
Number of subjects: 120
Study 19597412 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglucosamine (PG) 2 g/day
Number of subjects: 30
Study 17357520 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 60
Study 17357520 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem+SNP
Number of subjects: 60
Study 17357520 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol+SNP
Number of subjects: 60
Study 14572565 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5-h infusion of gabexate (500 mg total)
Number of subjects: 434
Study 14572565 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-h infusion of gabexate (1 g total)
Number of subjects: 434
Study 14572565 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 434
Study 10629468 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-component acellular pertussis vaccine (APV) composed of pertussis toxin and filamentous hemagglutinin
Number of subjects: 100
Study 10629468 — intervention group
Group type: COMPARATOR
Intervention: Meningococcal vaccine (control)
Number of subjects: 100
Study 8959467 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.55 g/kg of body weight)
Number of subjects: 10
Study 8959467 — intervention group
Group type: COMPARATOR
Intervention: Mineral water (control)
Number of subjects: 10
Study 1326741 — intervention group
Group type: EXPERIMENTAL
Intervention: D x RRV vaccine (10^4 plaque-forming units/1-ml dose)
Number of subjects: 359
Study 1326741 — intervention group
Group type: EXPERIMENTAL
Intervention: DS 1 x RRV vaccine (10^5 plaque-forming units/1-ml dose)
Number of subjects: 359
Study 1326741 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 359
Study 4048752 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone (2 g/d)
Number of subjects: 30
Study 4048752 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin (6 g/d) + Tobramycin (3 to 4 mg/kg/d)
Number of subjects: 30
Study 29553834 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dill vaginal suppositories
Number of subjects: 60
Study 29553834 — intervention group
Group type: COMPARATOR
Intervention: 100 mg clotrimazole vaginal tablets
Number of subjects: 60
Study 27999313 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infant, post‐discharge nutrition (PIN) program
Number of subjects: 22
Study 27999313 — intervention group
Group type: COMPARATOR
Intervention: Conventional nutrition services
Number of subjects: 22
Study 24115072 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-5334 immediate release tablet (IRT)
Number of subjects: 295
Study 24115072 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-5334 sustained release tablet (SRT)
Number of subjects: 295
Study 24115072 — intervention group
Group type: COMPARATOR
Intervention: Caucasian subjects
Number of subjects: 295
Study 24115072 — intervention group
Group type: COMPARATOR
Intervention: Japanese subjects
Number of subjects: 295
Study 20973828 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric elbow flexor exercise
Number of subjects: 0
Study 20151971 — intervention group
Group type: EXPERIMENTAL
Intervention: UK-369,003 (10, 25, 50 or 100 mg once a day for 12 weeks)
Number of subjects: 310
Study 20151971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 20151971 — intervention group
Group type: EXPERIMENTAL
Intervention: UK-369,003 (in subset with ED)
Number of subjects: 310